Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer
- William K. Oh
- , Matthew D. Galsky
- , Walter M. Stadler
- , Sandy Srinivas
- , Franklin Chu
- , Glenn Bubley
- , J. Goddard
- , Joi Dunbar
- , Robert W. Ross
Research output: Contribution to journal › Article › peer-review
68
Scopus
citations